Congressional negotiators included a provision in the current appropriations package that would create a streamlined pathway for Medicare coverage of FDA‑approved multi‑cancer early detection (MCED) tests without waiting for a USPSTF recommendation. The provision ties reimbursement to the rate for a multi‑target stool DNA colorectal screening test (~$509) and phases in eligibility starting in 2029. The change addresses a major commercial barrier for MCED developers who have argued that USPSTF endorsement is a lengthy bottleneck for Medicare access. Leerink Partners analysts noted the provision may not materially alter near‑term economics for some firms but could reshape market dynamics and payer negotiations over the medium term. If enacted, the policy would be a significant win for MCED companies seeking predictable reimbursement pathways and could influence private‑payer decisions and investment in population‑scale screening studies.